AMENDMENTS TO THE CLAIMS:

The following listing of claims replaces all prior listings, and all prior versions, of claims in the application.

Listing of Claims:

1. (Currently Amended) A pharmaceutical preparation comprising a compound (I),

which is obtained by reacting a ~~compound~~ peptide (II) having a free amino group and being a pharmaceutical compound ~~selected from the group B~~, with a sugar (III) having the reducing power and selected from the group A,

wherein the group A consists of lactose, sialyllactose and compounds prepared by chemically binding a polymer selected from the group consisting of polyoxyethylene, polyglutamic acid and polyvinylpyrrolidone to a hydroxyl group other than the hydroxyl group formed from the reducing aldehyde group of sugar selected from the group consisting of lactose and sialyllactose,

wherein an amino group of said ~~compound~~ peptide (II) reacts with an aldehyde group in said sugar (III); and

wherein said compound (I) can rapidly release said ~~compound~~ peptide (II) having a free amino group in response to changes in pH~~,~~

~~wherein the group B consists of doxorubicin and a peptide, and the group A consists of lactose, sialyllactose and compounds prepared by chemically binding a polymer selected from the group consisting of polyoxyethylene, polyglutamic acid and polyvinylpyrrolidone to a hydroxyl group other than the hydroxyl group formed~~

~~from the reducing aldehyde group of a sugar selected from the group C, wherein the group C consists of lactose and sialyllactose~~.

2. and 3. (Cancelled)

4. (Currently Amended) The preparation according to claim 1, wherein said peptide (II) is insulin.

5. - 20. (Cancelled)

21. (Currently Amended) The preparation according to claim 1, wherein said ~~compound~~ peptide (II) is enkephalin .

22. - 80. (Cancelled)

81. (New) The preparation according to claim 1, wherein said compound (I) is an unmodified compound (I) modified with a pharmaceutical carrier and which is obtained by the following steps:

said peptide (II) is modified with a pharmaceutical carrier, to provide a modified peptide, and said modified peptide is reacted with said sugar (III) to give said compound (I).

82. (New) The preparation according to claim 1, wherein said compound (I)

is an unmodified compound (I) modified with a pharmaceutical carrier and which is obtained by the following steps:

said peptide (II) is reacted with said sugar (III) to give said unmodified compound (I), and said unmodified compound (I) is modified with said pharmaceutical carrier.

83. (New) The preparation according to claim 1, wherein said compound (I) is encapsulated in a pharmaceutical carrier and which is obtained by the following steps:

said peptide (II) and said sugar (III) are encapsulated in a pharmaceutical carrier, and said peptide (II) is reacted with said sugar (III) to give said compound (I) in said pharmaceutical carrier.

84. (New) The preparation according to claim 1, wherein said compound (I) is encapsulated in a pharmaceutical carrier and which is obtained by the following steps:

said peptide (II) is reacted with said sugar (III) to give said compound (I), and said compound (I) is encapsulated in said pharmaceutical carrier.

85. (New) The preparation according to any one of claims 81-84, wherein said pharmaceutical carrier is selected from the group consisting of liposome, lipid emulsion, microemulsion, polymer micelle, microcapsule, microsphere and magnetic particles.

86. (New) The preparation according to claim 4, wherein said compound (I) is an unmodified compound (I) modified with a pharmaceutical carrier and which is obtained by the following steps:

insulin is modified with a pharmaceutical carrier, to provide modified insulin, and the modified insulin is reacted with said sugar (III) to give said compound (I).

87. (New) The preparation according to claim 4, wherein said compound (I) is an unmodified compound (I) modified with a pharmaceutical carrier and which is obtained by the following steps:

insulin is reacted with said sugar (III) to give said unmodified compound (I), and said unmodified compound (I) is modified with said pharmaceutical carrier.

88. (New) The preparation according to claim 4, wherein said compound (I) is encapsulated in a pharmaceutical carrier and which is obtained by the following steps:

insulin and said sugar (III) are encapsulated in a pharmaceutical carrier, and insulin is reacted with said sugar (III) to give said compound (I) in said pharmaceutical carrier.

89. (New) The preparation according to claim 4, wherein said compound (I) is encapsulated in a pharmaceutical carrier and which is obtained by the following steps:

insulin is reacted with said sugar (III) to give said compound (I), and said compound (I) is encapsulated in said pharmaceutical carrier.

90. (New) The preparation according to any one of claims 86-89, wherein said pharmaceutical carrier is selected from the group consisting of liposome, lipid emulsion, microemulsion, polymer micelle, microcapsule, microsphere and magnetic particles.

91. (New) The preparation according to claim 21, wherein said compound (I) is an unmodified compound (I) modified with a pharmaceutical carrier and which is obtained by the following steps:

enkephalin is modified with a pharmaceutical carrier to provide modified enkephalin, and the modified enkephalin is reacted with sugar (III) to give said compound (I).

92. (New) The preparation according to claim 21, wherein said compound (I) is an unmodified compound (I) modified with a pharmaceutical carrier and which is obtained by the following steps:

enkephalin is reacted with said sugar (III) to give said unmodified compound (I), and said unmodified compound (I) is modified with said pharmaceutical carrier.

93. (New) The preparation according to claim 21, wherein said compound (I) is encapsulated in a pharmaceutical carrier and which is obtained by the following

steps:

enkephalin and said sugar (III) are encapsulated in a pharmaceutical carrier, and enkephalin is reacted with said sugar (III) to give said compound (I) in said pharmaceutical carrier.

94. (New) The preparation according to claim 21, wherein said compound (I) is encapsulated in a pharmaceutical carrier and which is obtained by the following steps:

enkephalin is reacted with said sugar (III) to give said compound (I), and said compound (I) is encapsulated in said pharmaceutical carrier.

95. (New) The preparation according to any one of claims 91-94, wherein said pharmaceutical carrier is selected from the group consisting of liposome, lipid emulsion, microemulsion, polymer micelle, microcapsule, microsphere and magnetic particles.

96. (New) The preparation according to claim 1, wherein said group A consists of lactose and sialyllactose.

97. (New) The preparation according to claim 4, wherein said group A consists of lactose and sialyllactose.

98. (New) The preparation according to claim 21, wherein said group A

consists of lactose and sialyllactose.